Focus on Asthma Care

Back to articles

SMART therapy associated with a lower risk of asthma exacerbations

KEY POINT

A meta-analysis of 16 trials evaluating use of a single maintenance and reliever therapy (SMART), with the majority of studies using a combination of budesonide and formoterol in a dry-powder inhaler, found that the risk of asthma exacerbations was lower in patients using this regimen compared with an inhaled corticosteroid (ICS) as the controller therapy (with or without a long-acting beta-agonist [LABA]) plus a short-acting beta-agonist (SABA) as the relief therapy.